Abstract |
|
Authors | Julie R Brahmer, Hans Hammers, Evan J Lipson |
Journal | Future oncology (London, England)
(Future Oncol)
Vol. 11
Issue 9
Pg. 1307-26
( 2015)
ISSN: 1744-8301 [Electronic] England |
PMID | 25798726
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Antibodies, Monoclonal
- Antineoplastic Agents
- Biomarkers
- Programmed Cell Death 1 Receptor
- Nivolumab
|
Topics |
- Antibodies, Monoclonal
(pharmacology, therapeutic use)
- Antineoplastic Agents
(pharmacology, therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Biomarkers
- Clinical Trials, Phase I as Topic
- Clinical Trials, Phase II as Topic
- Clinical Trials, Phase III as Topic
- Female
- Humans
- Immunomodulation
(drug effects)
- Male
- Neoplasms
(diagnosis, drug therapy, immunology, metabolism)
- Nivolumab
- Programmed Cell Death 1 Receptor
(antagonists & inhibitors, metabolism)
- Treatment Outcome
|